Peptide programs
Peptide Marketing for Clinics, Telehealth Brands and Peptide Companies
There are two kinds of peptide businesses, and they play by different rules. We build the marketing for the one you actually run, and we’re plain about what each one can and can’t do.
The short answer
Peptide marketing is how a clinic, telehealth brand or peptide company attracts and keeps customers within the rules for its type of business. Prescribed peptide therapy can be marketed through provider-led education, SEO, email and a branded app. Research-use-only brands cannot make health or dosing claims, and most ad platforms restrict them. The right plan starts with knowing which business you are.
Written by Justin Ingram, founder of ModFX Media20+ years in medical sales, built and ran seven clinics, CMO of Heroship and ThriveLab, and owner of a 503A compounding pharmacy.Last updated October 8, 2026Where peptide regulation stands (as of October 2026)
As of October 2026. We update this quarterly.
- April 2026: The FDA removed 12 peptides, including BPC-157 and TB-500, from its Category 2 list, the list of bulk substances that raise significant safety concerns for compounding. Removal is not approval.
- July 2026: An FDA advisory committee voted to recommend BPC-157 (8 to 6) and KPV for the 503A bulks list, the list of substances a 503A compounding pharmacy (a state-licensed pharmacy that prepares medications for individual patient prescriptions) may use. That vote is advice, not a final rule. Formal rulemaking must follow.
- What it means for you: None of these steps makes a peptide “legal now.” Until a final rule is in place, what a pharmacy can compound depends on federal and state rules that your pharmacy partner and healthcare counsel confirm for your states.
Sources: Yoo Direct Health on the BPC-157, KPV and TB-500 news and New Drug Loft on compounded peptide updates. This box is educational, not legal advice.
Two kinds of peptide businesses, two playbooks
| Prescribed peptide therapy | Research-use-only (RUO) brand | |
|---|---|---|
| Who it serves | Patients, through a clinic or telehealth program | Buyers of products labeled for laboratory research, not human use |
| Who decides | A licensed provider evaluates and prescribes | No provider involved |
| Who fills it | A state-licensed pharmacy, for an individual prescription | A supplier, under your label |
| What marketing can say | The program, the provider, the process, and education your clinical team reviews | Product facts and research context only. No health claims, no dosing, no human-use language |
| Paid ads | Possible with provider-led creative. Prescription promotion on Google and Meta requires LegitScript certification | Most ad platforms restrict or block these products |
Playbook 1: prescribed peptide therapy
This is peptide telehealth and in-clinic peptide therapy. A licensed provider reviews each patient, often through an async visit (the patient fills out an intake and a provider reviews it later, no live video) or a video visit. When treatment fits, a licensed pharmacy fills the prescription.
The marketing sells access to that provider-led care. It still makes no outcome promises. And drug-specific ads on Google and Meta need LegitScript certification, the third-party certification Google and Meta check before they let a telehealth brand advertise prescription treatments.
Playbook 2: research-use-only brands
RUO (research use only) means the product is sold for laboratory research, not for people to use. That label sets hard limits. No health claims. No dosing. No “for recovery” or “for fat loss” language. No testimonials about how someone felt.
Here’s what is possible: a clean, fast store, SEO on product and research-category pages, email to opted-in lists, and partner programs held to the same claim rules. Here’s what isn’t: scaled Meta campaigns, or any copy that implies human use. If an agency promises otherwise, ask what happens to your ad account and merchant account when the platform disagrees.
What our peptide marketing includes
Here’s the operational detail that decides whether peptide SEO works. Google holds health pages to its highest quality bar, so a treatment page with no named clinical reviewer, no sources and no date tends to stall. Every page we publish carries all three, plus a review date your team actually keeps.
Education-first content
Plain-English pages and posts on what peptide therapy is, how a provider decides if it fits, and what questions to ask. Every clinical statement is reviewed by your providers before it publishes.
Provider-led video
Short videos your providers record, plus AI-assisted video and creator-style content we produce in-house. AI content is never presented as a real patient testimonial.
SEO for treatment and goal pages, with clinical review
This is the core of peptide clinic marketing: one page per treatment, goal and location, built on Next.js and Vercel and written to be read, understood, and cited by Google, ChatGPT and Perplexity. Meaningful organic traction typically takes 3 to 4 months.
Email programs
Onboarding, protocol check-ins, refill reminders and education, run on a HIPAA-compliant CRM built on GoHighLevel.
Your branded telehealth app, with protocol tracking
Built with Heroship, your branded telehealth app gives patients telehealth visits, peptide and GLP-1 protocol tracking, refills and orders, secure messaging and membership tiers you set. It connects to licensed providers and partner pharmacies in all 50 states through the Heroship and Wizlo networks. Which treatments a patient can receive still depends on the medication and state rules. App Store submission typically comes about 30 days into the build, and Apple’s review time is outside our control.
How to sell peptides the compliant way
If your goal is helping people use peptides, the prescribed path is the one built for it. Here’s the order we walk founders through:
- Choose your model. Prescribed therapy or RUO. Write every word of your marketing for that business only.
- Set up the clinical side. You need licensed providers in each state you serve, a medical group, and a state-licensed 503A pharmacy partner.
- Pick a legal structure with counsel. Many non-physician founders use an MSO and friendly PC model: a management services organization runs the business side, and a professional corporation owned by a licensed physician handles the medicine. Corporate practice of medicine rules, which limit who can own or control a medical practice, vary by state. Work with healthcare counsel.
- Confirm what your pharmacy can compound today. Status is changing in 2026. See the dated box above.
- Build the infrastructure. Branded site, intake, payments, and LegitScript where needed.
- Market education first, provider led.
- Plan the next step before a protocol ends. Patients who finish a protocol with no plan tend to leave. A provider check-in before the end keeps the relationship.
“Do I need to be a doctor to start a peptide business?” No. Many founders aren’t clinicians. But the medical decisions belong to licensed providers, and the ownership structure has to fit your state’s rules. That’s the part to get right with counsel before you spend on ads.
From the field
I own a 503A compounding pharmacy and run marketing for telehealth brands, so I see peptides from the pharmacy counter and the ad account at the same time. The founders who get hurt here usually aren’t bad actors. They took an RUO playbook and ran it like a clinic, or pasted clinic copy onto an RUO store. Both break. My rule is simple: decide which business you are on day one and write every word for that business. The rules are moving fast in 2026, and the brands still standing next year will be the ones whose marketing never got ahead of the law.
Justin Ingram
GLP-1s and peptides: one patient journey
GLP-1 medications are peptides too. Many patients first find a provider-led program through a weight goal. Over time, some ask their provider about other goals, and the provider decides whether any other prescribed therapy fits.
When the same provider team, the same app and the same care plan can answer those questions, the patient stays with you. That’s how GLP-1s and peptides together raise lifetime value: one relationship, more reasons to stay, every step provider-led.
The ad rules for the GLP-1 side are their own topic. Our GLP-1 marketing page covers them in detail, and our telehealth marketing guide and telehealth launch and marketing hub show how it all fits together.
What happens on the strategy call
What we cover
Where you are today and where you want to be in 12 months. Your treatments, states and timeline. What is already working and what is leaking. The path we would take, in order, and whether we are the right team for it. If we are not, we will tell you who is.
What to bring
Your treatment list and target states. Current numbers if you are live (ad spend, new patients, refill rate). The platforms or vendors you are considering. Rough is fine.
About cost: Every launch is scoped to your states, product mix and goals, so we put real numbers in front of you on the call.
Book a strategy callYou’ll leave knowing which peptide playbook fits your business, which channels are actually open to you, and what your pharmacy and counsel need to confirm first.
FAQ
+How do I start a peptide business?
Start by choosing your model. To offer peptide therapy to patients, you need licensed providers, a medical group and a state-licensed 503A compounding pharmacy partner, under a structure your healthcare counsel approves for your states. To sell research-use-only products, you need a supplier, a compliant store and copy with no health or dosing claims. You don’t need to be a clinician to own either, but rules vary by state.
+Can I run Meta ads for peptides?
It depends on which peptide business you run. Prescribed peptide programs can run education-first, provider-led Meta ads, and promoting prescription treatment requires LegitScript certification and Meta’s approval. RUO brands are generally restricted on Meta, and ads that imply human use put the ad account and the business behind it at risk. We tell you plainly which campaigns are possible before any budget goes out.
+What’s the difference between RUO peptides and prescribed peptides?
Prescribed peptides are prepared by a licensed pharmacy for a specific patient after a licensed provider evaluates them and writes a prescription. RUO (research use only) peptides are sold for laboratory research and are not for human use, so they can’t carry health claims, dosing or usage guidance. The two need different websites, ad strategies and compliance reviews. Mixing their language is where brands get into trouble.
+Is BPC-157 legal now?
Its status is pending as of October 2026. In April 2026 the FDA removed BPC-157 from its Category 2 safety-concern list, and in July 2026 an FDA advisory committee voted 8 to 6 to recommend it for the 503A bulks list. Removal is not approval, and a committee vote is advice, not a final rule. Formal rulemaking must follow. Check with healthcare counsel and your pharmacy before marketing it.
+Can you help me white label a peptide line?
Yes. White label means you sell under your own brand while partners provide what sits behind it. For prescribed peptides, that’s licensed providers, a medical group and a 503A pharmacy, with your brand on the program. For RUO, it’s your label on products from a supplier, with no health claims. Our white label telehealth page explains how the prescribed version works.
Build a peptide business that lasts past the next rule change
Tell us which peptide business you run, or plan to, and we’ll map the marketing that fits.
Map my peptide marketing planSources
ModFX Media is a marketing agency, not a medical provider, pharmacy or law firm. This page is educational and is not medical or legal advice. Whether a treatment is right for a patient is decided by a licensed provider, and availability depends on the medication and state rules.